Legend

Tet-switchable AP-1 transgenic mice were generated for ectopic expression of specific AP-1 monomers/dimers in skin, bone, liver and lung, and are complemented by tissue/cell specific loss-of-function mouse models. Proteomics, expression profiling, RNA-sequencing and ChIP-sequencing are employed to compare mouse models to human disease and to identify novel targets. Furthermore, we are investigating the systemic response of the mouse organism to a growing tumour in cancer cachexia. Preclinical studies are performed using different genetically engineered mouse models with compounds that target the identified molecules to translate our findings to patient management.